NRX Pharmaceuticals Inc. (NASDAQ: NRXP) has reported its financial results for the first quarter ended March 31, 2025. The company recorded a net loss of $5.5 million, an improvement from the net loss of $6.5 million in the same quarter of 2024. The loss from operations decreased to $3.8 million compared to $6.0 million in the previous year. Research and development expenses were reduced to $0.8 million from $1.7 million, while general and administrative expenses decreased to $2.9 million from $4.3 million in the corresponding 2024 quarter. As of March 31, 2025, NRX Pharmaceuticals held approximately $5.5 million in cash and cash equivalents. Operationally, the company has progressed in its strategy to gain FDA approval for two new drugs and to expand its network of clinics specializing in neuroplastic therapies for severe depression and PTSD. These initiatives contribute to the company's corporate goal of developing HOPE Therapeutics into a national network of interventional psychiatry clinics. NRX Pharmaceuticals also executed a term sheet for $10.3 million in acquisition capital to support the expansion of its clinic network, reflecting its commitment to advancing mental health treatments.